"Making impacts on science and making impacts on patients. Being able to do both as a scientist at Genentech is incredible rewarding."
I joined Genentech in 2011. As a Senior Principal Scientist in the Department of Oncology Biomarker, I lead the translation and reverse translation studies in liver cancer and ovarian cancer disease areas as well as global combination immunotherapy development. By integrating cancer genomics, digital pathology, ctDNA and single cell multi-omics in clinical biomarker studies, my team has gained novel insights into potential mechanisms of response and resistance to cancer immunotherapies.
Becoming a postdoc mentor has been the most exciting and rewarding experience for me. The postdoc program provides us an excellent opportunity to gain insights into disease biology and mechanism of response and resistance in drug development via cutting-edge translation and reverse translation research.
Cancer Cell. 2021 Jul 12;39(7):928-944.e6. doi: 10.1016/j.ccell.2021.04.004. Epub 2021 May 6.
Immunol Rev. 2021 Jul;302(1):241-258. doi: 10.1111/imr.12982. Epub 2021 Jun 1.
2020 Nov 5;11:598877. doi: 10.3389/fimmu.2020.598877.
Nat Commun. 2020 Nov 4;11(1):5583. doi: 10.1038/s41467-020-19408-2.
2020 Jun;22(6):770-781. doi: 10.1016/j.jmoldx.2020.02.013. Epub 2020 Apr 2.
J Mol Diagn. 2017 Nov;19(6):921-932. doi: 10.1016/j.jmoldx.2017.08.001. Epub 2017 Sep 1.
Clin Cancer Res. 2015 Jul 1;21(13):2941-51. doi: 10.1158/1078-0432.CCR-14-3111. Epub 2015 Apr 2.
Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26.
My group’s translational research focuses on understanding the heterogeneity of the disease biology, tumor immune microenvironment and stroma biology to guide the development of novel therapeutic and diagnostic strategies.